Tumor Models

 Discover our tumor models for oncology proof of concept

Oncodesign Services offers a range of discovery & preclinical services built upon a tumor models of syngeneic, cell-derived xenograft (CDX) and patient-derived xenograft (PDX) tumors.

Over 500 syngeneic, CDX and PDX tumor models are established in-house, covering 20 organ origins and up to 35 pathologies:  bladder, blood, brain, breast, cervix, colon, head and neck, kidney, liver, lung, skin (melanoma), muscle, osteosarcoma, ovary, pancreas, prostate, Schwann cell, stomach and more.  These cover solid tumors, hematological malignancies and metastasis models.

Tumors are used for  in vivo modeling in vitro screening and for target expression analysis. The tumors are stored as viable frozen stocks for propagation and often in FFPE blocks for ex vivo analysis of the TME.  Please ask for slide samples.

Tumor Models - table of models Syngeniec, CDX, PDX & humanized mouse_V2
  • Popular Human CDX Models
    Breast MX-1 | MDA-MB-468 | MCF-7 
    Colon HCT-116| Ls174T
    Lung Calu-6 | NCI-H46
    Prostate PC-3
    Brain U-87 MG
  • Well Characterized Mouse Syngeneic Models
    Bladder MBT-2
    Breast EMT6 | 4T1 (Mets to lung)
    Colon C26 | C38 | MC38 | CT26 (Mets to lung)
    Kidney renca (mets to lung)
    Melanoma B16F10 (Mets to lung)
    Mesothelioma AB12
    Liver Hepa 1-6
    Lung LLc1 (Mets to lung)
    Pancreas Pan02
    Lymphoma A20
    Plasmacytoma MPC-11
    Osteosarcoma NCTC-2472 (Mets)



  • Patient-Derived Xenografts (PDX)

    Oncodesign has collected PDX tumors for over 25 years, in partnership with the IMODI consortium. Currently, we have >200 unique tumors, covering 19 indications. These tumors have been characterized in regard to:

    • Histology
    • Conservation of phenotype and genotype
    • Gene expression stability
    • Gene mutation status
    • Response to standard of care (SOC)

    If the model you need requires a specific gene expression or gene mutation, please ask us to query the transcriptome. Many tumors are available as tissue microarray slides, cut from FFPE blocks.

  • Rat Models
    Colon DHD/K12/TRb (PROb)*
    Brain GV1A1*
    Bladder AY-27
    Breast MAT-B-III
    Head & Neck FAT-7
    Brain GS-9L
    Prostate R3327H*
    Prostate Mat-Ly-Lu*
    Breast DMBA-induced

All syngeneic and CDX tumors are also available for in vitro, cell-based assays.
Read about Oncodesign Services’ in vitro biology here. 

CASE STUDY with tumor model :

The U-87-MG brain glioblastoma CDX was used as a SC model in rats for a study of sorafenib and temozolomide. Negative control animals had exponential tumor growth after about 30 days. Sorafenib delayed the tumor growth and temozolomide completely attenuated the tumor growth in this model.


Tumor bank - U-87 MG brain glioblastoma_V2